Last reviewed 2026-04-23 · How we verify

AXR-270 Low Dose

AxeroVision, Inc. · Phase 2 active Small molecule

AXR-270 Low Dose is a SGLT2 inhibitor Small molecule drug developed by AxeroVision, Inc.. It is currently in Phase 2 development for Type 2 diabetes.

AXR-270 Low Dose is a small molecule that targets the SGLT2 receptor.

AXR-270 Low Dose is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.

At a glance

Generic name	AXR-270 Low Dose
Sponsor	AxeroVision, Inc.
Drug class	SGLT2 inhibitor
Target	SGLT2
Modality	Small molecule
Therapeutic area	Diabetes
Phase	Phase 2

Mechanism of action

AXR-270 Low Dose works by inhibiting the SGLT2 receptor, which reduces glucose reabsorption in the kidneys and lowers blood glucose levels. This mechanism is similar to other SGLT2 inhibitors, but with a lower dose to minimize side effects.

Approved indications

Type 2 diabetes

Common side effects

Nausea
Diarrhea
Vomiting

Key clinical trials

Evaluation of AXR-270 for the Treatment of Posterior Blepharitis Associated With Meibomian Gland Dysfunction (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

AXR-270 Low Dose CI brief — competitive landscape report
AXR-270 Low Dose updates RSS · CI watch RSS
AxeroVision, Inc. portfolio CI

Frequently asked questions about AXR-270 Low Dose

What is AXR-270 Low Dose?

AXR-270 Low Dose is a SGLT2 inhibitor drug developed by AxeroVision, Inc., indicated for Type 2 diabetes.

How does AXR-270 Low Dose work?

AXR-270 Low Dose is a small molecule that targets the SGLT2 receptor.

What is AXR-270 Low Dose used for?

AXR-270 Low Dose is indicated for Type 2 diabetes.

Who makes AXR-270 Low Dose?

AXR-270 Low Dose is developed by AxeroVision, Inc. (see full AxeroVision, Inc. pipeline at /company/axerovision-inc).

What drug class is AXR-270 Low Dose in?

AXR-270 Low Dose belongs to the SGLT2 inhibitor class. See all SGLT2 inhibitor drugs at /class/sglt2-inhibitor.

What development phase is AXR-270 Low Dose in?

AXR-270 Low Dose is in Phase 2.

What are the side effects of AXR-270 Low Dose?

Common side effects of AXR-270 Low Dose include Nausea, Diarrhea, Vomiting.

What does AXR-270 Low Dose target?

AXR-270 Low Dose targets SGLT2 and is a SGLT2 inhibitor.

Drug class: All SGLT2 inhibitor drugs
Target: All drugs targeting SGLT2
Manufacturer: AxeroVision, Inc. — full pipeline
Therapeutic area: All drugs in Diabetes
Indication: Drugs for Type 2 diabetes
Compare: AXR-270 Low Dose vs similar drugs
Pricing: AXR-270 Low Dose cost, discount & access